ACCESSION: MSBNK-SMB_Measured-HSA015P0409001
RECORD_TITLE: Uncharacterized; LC-ESI-QFT; MS2; POSITIVE; Averaged data
DATE: 2025.03.05 (Averaged 2025.02.21, Processed 2025.02.21, Annotated 2025.03.05, Curated 2025.03.05)
AUTHORS: Shin-MassBank project
LICENSE: CC BY-NC-SA
PUBLICATION: Ruggiero et al. Int J Cancer. 2023, 153, 1, 210-223
COMMENT: This is an averaged mass spectra data created by averaging product ion scan data obtained from the following DDA dataset.
COMMENT: REPOSITORY MetaboLights
COMMENT: DATASET_ID MTBLS6402
COMMENT: DATASET_TITLE FSCN1 as a new druggable target in adrenocortical carcinoma
COMMENT: DATASET_AUTHORS Andrei Turtoi, Enzo Lalli
COMMENT: MS1_M/Z_AVERAGED_THRES 5.000
COMMENT: MS2_M/Z_AVERAGED_THRES 5.000
COMMENT: DATASET_FILE_NUM 27
COMMENT: NUM_AVERAGED_SPEC 14
COMMENT: RAW_SPEC {'EL07_pos_9455': {'bp': 331238.0, 'sum': 460331.0}, 'EL18_pos_9460': {'bp': 232402.0, 'sum': 323084.0}, 'EL01_pos_9453': {'bp': 229414.0, 'sum': 313441.0}, 'EL05_pos_9525': {'bp': 227638.0, 'sum': 336452.0}, 'EL02_pos_9550': {'bp': 213388.0, 'sum': 279565.0}, 'EL11_pos_9455': {'bp': 201330.0, 'sum': 311056.0}, 'EL09_pos_9471': {'bp': 190573.0, 'sum': 294148.0}, 'EL14_pos_9485': {'bp': 174720.0, 'sum': 255752.0}, 'EL06_pos_9501': {'bp': 159693.0, 'sum': 237474.0}, 'EL20_pos_9466': {'bp': 143930.0, 'sum': 224223.0}, 'EL04_pos_9455': {'bp': 143759.0, 'sum': 249994.0}, 'EL13_pos_9479': {'bp': 125228.0, 'sum': 173258.0}, 'EL17_pos_9491': {'bp': 110751.0, 'sum': 165653.0}, 'EL24_pos_9467': {'bp': 85571.0, 'sum': 128574.0}}
COMMENT: RETENTION_TIME_STDEV 0.006
COMMENT: PRECURSOR_M/Z_RAW 409.175225
COMMENT: PRECURSOR_M/Z_STDEV 0.000123
COMMENT: PRECURSOR_IN_MS1 mz 409.175178; int 47.756; delta(ppm) 1.010138
COMMENT: PROPOSED_CHARGE_STATE +1; mz 410.178463; int 9.541; cor 0.832
COMMENT: PROPOSED_ISOTOPE_STATE ND
COMMENT: PROPOSED_ION_FORM M+H; M+ACN+H; mz 450.202319; int 3.574; cor 0.758
COMMENT: PROPOSED_ION_FORM M+Na; M+H; mz 387.193250; int 156.726; cor 0.873
COMMENT: PROPOSED_ION_FORM M+Na; M+ACN+Na; mz 450.202319; int 3.574; cor 0.758
COMMENT: PROPOSED_ION_FORM M+ACN+H; M+2ACN+H; mz 450.202319; int 3.574; cor 0.758
COMMENT: PROPOSED_ION_FORM M+2Na-H; M+Na; mz 387.193250; int 156.726; cor 0.873
COMMENT: PROPOSED_MAX_NUM_S 0
COMMENT: PROPOSED_MF SevenGoldenRules 3.033; C15H30N4O5P2; [M+H]+; delta(ppm) -3.033066
COMMENT: PROPOSED_MF SevenGoldenRules 1.519; C23H24N2O5; [M+H]+; delta(ppm) -1.518983
COMMENT: PROPOSED_MF SevenGoldenRules 0.243; C14H34O9P2; [M+H]+; delta(ppm) 0.242547
COMMENT: PROPOSED_MF SevenGoldenRules 4.290; C16H29N2O8P; [M+H]+; delta(ppm) 4.289901
COMMENT: PROPOSED_MF SevenGoldenRules 3.110; C20H27N4O2P; [M+Na]+; delta(ppm) -3.109901
COMMENT: PROPOSED_MF SevenGoldenRules 0.352; C19H31O6P; [M+Na]+; delta(ppm) 0.352162
COMMENT: PROPOSED_MF SevenGoldenRules 3.030; C13H32N4O5P2; [M+Na]+; delta(ppm) 3.029629
COMMENT: PROPOSED_MF SevenGoldenRules 4.630; C21H26N2O5; [M+Na]+; delta(ppm) 4.629894
COMMENT: PROPOSED_MF SevenGoldenRules 3.367; C13H27N3O5P2; [M+ACN+H]+; delta(ppm) -3.366551
COMMENT: PROPOSED_MF SevenGoldenRules 1.683; C21H21NO5; [M+ACN+H]+; delta(ppm) -1.683275
COMMENT: PROPOSED_MF SevenGoldenRules 1.133; C15H22N5O4P; [M+ACN+H]+; delta(ppm) 1.133079
COMMENT: PROPOSED_MF SevenGoldenRules 4.775; C14H26NO8P; [M+ACN+H]+; delta(ppm) 4.774728
COMMENT: PROPOSED_MF SevenGoldenRules 4.605; C12H32N2O10; [M+2Na-H]+; delta(ppm) -4.604562
COMMENT: PROPOSED_MF SevenGoldenRules 1.222; C16H34N2O3P2; [M+2Na-H]+; delta(ppm) -1.221843
COMMENT: PROPOSED_MF SevenGoldenRules 0.475; C24H28O3; [M+2Na-H]+; delta(ppm) 0.475008
COMMENT: PROPOSED_MF SevenGoldenRules 3.314; C18H29N4O2P; [M+2Na-H]+; delta(ppm) 3.314077
COMMENT: PROPOSED_COMPOUND SIMILARITY:GNPS 6.000; XBYUUOMUOFZSBJ-UHFFFAOYSA-N; C23H24N2O5; 2-(5-methoxy-4,8,8-trimethyl-2-oxo-2,8,9,10-tetrahydropyrano[2,3-f]chromen-3-yl)-N-(pyridin-2-yl)acetamide
COMMENT: PROPOSED_COMPOUND SIMILARITY:GNPS 2.000; WJQLYTQYMSTZJJ-UHFFFAOYSA-N; C23H24N2O5; N-(pyridin-2-yl)-2-((3,4,8,8-tetramethyl-2-oxo-2,8,9,10-tetrahydropyrano[2,3-f]chromen-5-yl)oxy)acetamide
COMMENT: CONFIDENCE Level 5: Exact mass of interest 409.175178; Observed in MS1; Charge state +1;
CH$NAME: Uncharacterized
CH$COMPOUND_CLASS: Uncharacterized
CH$FORMULA: C39H42O2
CH$EXACT_MASS: 542.318480
CH$SMILES: CCCC#Cc1cc(C#CCCC)cc(C#Cc2cc(C#CC(C)(C)C)c(cc2C#CC(C)(C)C)C2OCCO2)c1
CH$IUPAC: InChI=1S/C39H42O2/c1-9-11-13-15-30-25-31(16-14-12-10-2)27-32(26-30)17-18-33-28-35(20-22-39(6,7)8)36(37-40-23-24-41-37)29-34(33)19-21-38(3,4)5/h25-29,37H,9-12,23-24H2,1-8H3
CH$LINK: PUBCHEM CID:11353257
SP$SCIENTIFIC_NAME: Homo sapiens
SP$LINK: NCBI-TAXONOMY 9606 
SP$SAMPLE: Cell
AC$INSTRUMENT: Vanquish Flex UHPLC system, Thermo Fisher Scientific - Orbitrap Q Exactive Plus mass spectrometer, Thermo Fisher Scientific
AC$INSTRUMENT_TYPE: LC-ESI-QFT
AC$MASS_SPECTROMETRY: MS_TYPE MS2
AC$MASS_SPECTROMETRY: ION_MODE POSITIVE
AC$MASS_SPECTROMETRY: COLLISION_ENERGY Ramped collision energies of 40 V
AC$MASS_SPECTROMETRY: FRAGMENTATION_MODE CID
AC$MASS_SPECTROMETRY: ION_SPRAY_VOLTAGE 4.0 kV
AC$MASS_SPECTROMETRY: IONIZATION ESI
AC$MASS_SPECTROMETRY: MASS_ACCURACY MS1(ppm) 5.00; MS2(ppm) 5.00
AC$CHROMATOGRAPHY: COLUMN_NAME ZORBAX Pursuit 3 PFP (3 Âµm, 2.0 mm x 150 mm; Agilent Technologies)
AC$CHROMATOGRAPHY: FLOW_GRADIENT The gradient profile was linear decrease from 0-25% B from 0-2 min; fast linear increase from 25-35% B from 2-11 min; 95% B hold from 15-20 min;fast linear decrease from 95-0% B from 20-21 min. 
AC$CHROMATOGRAPHY: RETENTION_TIME 15.426
MS$FOCUSED_ION: PRECURSOR_M/Z 409.175178
MS$DATA_PROCESSING: RECALIBRATE Data dependent recalibration using whole DDA dataset
PK$SPLASH: splash10-0a4i-0000900000-a103e1e3e72933ed231d
PK$ANNOTATION: m/z int annotation m/z_nocal m/z_std(ppm) int_std cor n
  86.0964457 34.0306 ? 86.097152 1.0686 21.94 0.1538 13
  409.1749368 999.0000 ? 409.175397 0.3617 0.00 1.0000 14
  410.1783444 209.2231 ? 410.178805 1.0508 13.10 0.9824 14
PK$NUM_PEAK: 3
PK$PEAK: m/z int. rel.int.
  86.096446 34.03 34
  409.174937 999.00 999
  410.178344 209.22 209
//
